Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 31/12/2022
Compliance Officer - 31/12/2021
Investor Relations Contact - 31/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/25 Issuer sale

Director

85,011 0.1134%
01/07/25 Issuer sale

Chief Financial Officer

738,955 0.9861%
01/07/25 Issuer sale

Chief Technology Officer

151,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%+0.06% - - 3.54B
-1.13%-1.17%+38.55%+139.23% 1,261B
-1.36%-0.74%+39.64%+86.06% 671B
-0.59%-0.36%+25.14%+111.73% 518B
+0.11%+1.07%+32.44%+71.28% 387B
-0.75%-3.16%+54.39%+40.90% 353B
-0.35%-0.05%+30.08%+57.43% 300B
-0.58%-1.32%+1.08%+35.68% 283B
-0.95%-1.57%+34.01%+72.55% 248B
+1.60%-0.36%+37.21%+125.66% 211B
Average -0.34%-0.37%+32.50%+82.28% 470B
Weighted average by Cap. -0.45%-0.55%+34.41%+95.71%
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - SpringWorks Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SWTX Stock